Exercise caution in patients w/ allergic reaction to anti-inflammatory medications that are not derived from cortisone, & in those who are using other drugs. Stop treatment in case of skin rash. Risk of premature closure of ductus arteriosus & potential to prolong parturition if used during the 3rd trimester of pregnancy. Should not be used during the 1st & 2nd trimesters of pregnancy unless expected benefits to mother outweigh risks to fetus. If treatment is considered necessary to be administered anywhere from the middle (onset at approx 20 wk) to the end of the 2nd trimester of pregnancy, limit use to the lowest effective dose & shortest duration possible, & consider ultrasound monitoring of amniotic fluid if treatment extends >48 hr, & discontinue treatment if oligohydramnios occurs.
Sign Out
